Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., . . . Maguire, A. M. (2016). Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutatons: A follow-on phase 1 trial. Lancet.
Citação norma ChicagoBennett, Jean, et al. "Safety and Durability of Effect of Contralateral-eye Administration of AAV2 Gene Therapy in Patients With Childhood-onset Blindness Caused By RPE65 Mutatons: A Follow-on Phase 1 Trial." Lancet 2016.
MLA CitationBennett, Jean, et al. "Safety and Durability of Effect of Contralateral-eye Administration of AAV2 Gene Therapy in Patients With Childhood-onset Blindness Caused By RPE65 Mutatons: A Follow-on Phase 1 Trial." Lancet 2016.